Atherotech to exhibit VAP Cholesterol Test at ACC 2010

Atherotech Inc. today announced it will be presenting research in two poster sessions and exhibiting its VAP® Cholesterol Test in booth #1311 at the American College of Cardiology (ACC) 59th Annual Scientific Session Exposition. The annual meeting takes place March 14-16, 2010, at the Georgia World Congress Center in Atlanta.  

The VAP (Vertical Auto Profile) Test, which identifies a far greater number of people at risk for heart disease than standard cholesterol tests, was utilized in Atherotech-sponsored research to be presented at the conference. This research is being presented at the Sub-classes of Lipoproteins session and the Epidemiology session in Hall B of the Georgia World Congress Center.

"The VAP Test continues to prove its value in the laboratory as an analytical research tool and in thousands of doctors' offices across the U.S. as a direct-measured, comprehensive lipid assessment," said Atherotech Chief Medical Officer Michael Cobble, M.D.

Poster presentation 1075-103 titled "Subfractions As Predictors of Angiographic Coronary Artery Disease Among Those With Normal and Abnormal LDL Levels" is being presented from 3:30-4:30 p.m. on Sunday, March 14. Poster presentation 1128-96 "Apolipoprotein AI Predicts Future Death and Myocardial Infarction in Patients Undergoing Coronary Angiography Even When They Have Normal Baseline HDL Levels" is being presented from 9:30-10:30 a.m. on Monday, March 15. Both presentations are moderated by Heidi T. May, Ph.D., M.S.P.H., an epidemiologist at the Intermountain Medical Center in Murray, Utah.

Information related to the above presentations is embargoed until the time of scientific presentation. Additional information will be presented at the scientific session.

Atherotech representatives will be available to discuss the VAP Cholesterol Test in booth #1311, and blood draws will be provided to qualified attendees during regular exhibit hours. Because LDL is directly measured, fasting is not required. Test results will be returned to individuals via mail after the ACC conference. However, results for individuals tested Sunday will be available at the Atherotech booth Tuesday prior to the end of the conference.

The VAP Test reports 22 separate components of cholesterol and is covered by Medicare and most private insurance carriers. Unlike other lipid profiles, the VAP Test includes Lp(a) at no additional cost, and reports all three lipoprotein parameters -- LDL, non-HDL and apoB -- considered necessary by the expert consensus guidelines issued by the American Diabetes Association and American College of Cardiology. The VAP Test also identifies markers of metabolic syndrome, which is frequently associated with early diabetes, and is the only single cholesterol test that routinely reports apoAI, apoB and the apoB/apoAI ratio.